Ten Deals Completed

The Queen City Angels investment group and the QCA First Fund, members of the C-Cap angel investor network, made ten investments in the 12 months ending June, 2007.

RhinoCyte. RhinoCyte is developing diagnostic tools and therapies for the stem cell treatment of multiple degenerative and traumatic neurological diseases, using cells from the patient's own nasal cavity, eliminating the need for immunosuppressive therapy. This process could eventually be used to treat conditions such as Parkinson's disease, multiple sclerosis, Alzheimer's disease and spinal cord injuries.

AssureRx. Using technology developed and proven at Cincinnati Children’s’ Hospital combined with additional technology from Mayo Clinic, AssureRx will provide a diagnostic test to physicians. By analyzing the patient’s DNA and medical history, the test will enable them to drastically reduce the trial and error currently used to select the type and dosage of drugs that they prescribe for patient.

Minimally Invasive Devices LLC. This Ohio company is developing special-purpose medical instrumentation to enable surgeons to perform complex laparoscopic, or minimally invasive, surgical procedures. The Queen City Angels co-invested in this deal with the Ohio TechAngels investment group of Columbus, Ohio.

Spine Form LLC. This medical device company has emerged from breakthrough research in treating scoliosis at Cincinnati Children’s Hospital Medical Center. Its HemiBridge™ product is a minimally invasive treatment for scoliosis, without the need for spinal fusion.

Alta Financial Technologies uses financial rewards solutions to build loyalty in philanthropic individuals of all ages, incomes, and social status.  The company enables the general public to make online donations to their favorite nonprofits, receive a tax deduction, and earn lifetime loyalty rewards.

Tradicom has developed and will  manufacture a new generation of vending machine. The Chef 24/7™ will deliver a perfectly cooked meal or snack to the consumer in 90 seconds or less. In addition, the machine's touch screen will be networked to provide advertising to a captive audience while the food is being cooked.

Perseverance Group. The Perseverance Group plans to deliver a new subscription-based solution to help colleges and universities retain students.   The company will deliver secure online mentoring programs connecting alumni to students to keep both constituencies engaged with the institution. This will generate higher retention rates resulting in increased tuition revenue and a new way for alumni to “give back”.

Akebia Therapeutics is a start-up pharmaceutical company which has licensed select, high-quality drug development programs and assets from P&G. The company’s focus is on clinical development of novel compounds targeted for treatment of anemia and ischemia-related disorders. One of the primary ischemia-related products will be for treatment of peripheral artery disease (PAD).

Xanthostat Diagnostics has developed and is pursuing FDA 510k approval for its initial product, which will measure bilirubin and hemoglobin concentrations in spinal fluid. This test will be an important advancement in the early and accurate diagnosis of subarachnoid hemorrhage. The company is using technology developed at and licensed from the University of Cincinnati.